|
1) Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome？ Int J Biochem Cell Biol. 2003; 35: 807-25
|
|
|
|
2) Cambell DJ, Habener JF. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology. 1987; 121: 1616-26
|
|
|
|
|
|
3) Massiera F Seydoux J, Geloen A, et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology. 2001; 142: 5220-5
|
|
|
|
|
|
4) Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001; 15: 2727-9
|
|
|
|
|
|
5) Yvan-Charvet L, Even P, Bloch-Faure M, et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes. 2005; 54: 991-9
|
|
|
|
|
|
6) Yvan-Charvet L, Even P, Lamande N, et al. Prevention of adipose tissue depletion during food deprivation in angiotensin type 2 receptor-deficient mice. Endocrinology. 2006; 147: 5078-86
|
|
|
|
|
|
7) Kouyama R, Suganami T, Nishida J, et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology. 2005; 146: 3481-9
|
|
|
|
|
|
8) Matsushita K, Wu Y, Okamoto Y, et al. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension. 2006; 48: 1095-102
|
|
|
|
|
|
9) Geffroy S, De Vos P, Staels B, et al. Localization of the human OB gene (OBS) to chromosome 7q32 by fluorescence in situ hybridization. Genomics. 1995; 28: 603-4
|
|
|
|
|
|
10) Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995; 269: 540-3
|
|
|
|
|
|
11) Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin—the classical, resistin—the controversical, adiponectin—the promising, and more to come. Best Pract Res Clin Endocrinol Metab. 2005; 19: 525-46
|
|
|
|
|
|
12) Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001; 411: 480-4
|
|
|
|
|
|
13) Satoh N, Ogawa Y, Katsuura G, et al. Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes. 1999; 48: 1787-93
|
|
|
|
|
|
14) Mark AL, Correia ML, Rahmouni K, et al. Loss of leptin actions in obesity: two concepts with cardiovascular implications. Clin Exp Hypertens. 2004; 26: 629-36
|
|
|
|
|
|
15) Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 2000; 105: 1243-52
|
|
|
|
|
|
16) Correia ML, Morgan DA, Sivitz WI, et al. Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension. 2001; 37: 936-42
|
|
|
|
|
|
17) Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998; 12: 57-65
|
|
|
|
|
|
18) Quehenberger P, Exner M, Sunder-plassmann R et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res. 2002; 90: 711-8
|
|
|
|
|
|
19) Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes. 1999; 48: 903-8
|
|
|
|
|
|
20) Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension. 2001; 37: 670-6
|
|
|
|
|
|
21) Ouchi N, Kihara S, Funahashi T, et al. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol. 2003; 14: 561-6
|
|
|
|
|
|
22) Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423: 762-9
|
|
|
|
|
|
23) Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002; 277: 25863-6
|
|
|
|
|
|
24) Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002; 8: 731-7
|
|
|
|
|
|
25) Francischetti EA, Celoria BM, Duarte SF, et al. Hypoadiponectinemia is associated with blood pressure increase in obese insulin-resistant individuals. Metabolism. 2007; 56: 1464-9
|
|
|
|
|
|
26) Ohashi K, Kihara S, Ouchi N, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension. 2006; 47: 1108-16
|
|
|
|
|
|
27) Tanida M, Shen J, Horii Y, et al. Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med. 2007; 232: 390-7
|
|
|
|
|
|
28) Ran J, Hirano T, Fukui T, et al. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism. 2006; 55: 478-88
|
|
|
|
|
|
29) Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002; 8: 731-7
|
|
|
|
|
|
30) Bjursell M, Ahnmark A, Bohlooly-Y M, et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes. 2007; 56: 583-93
|
|
|
|
|
|
31) Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001; 409: 307-12
|
|
|
|
|
|
32) Dick GM, Katz PS, Farias M 3rd, et al. Resistin impairs endothelium-dependent dilation to bradykinin, but not acetylcholine, in the coronary circulation. Am J Physiol Heart Circ Physiol. 2006; 291: H2997-3002
|
|
|
|
|
|
33) Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf). 2006; 64: 355-65
|
|
|
|
|
|
34) O'Dowd BF, Heiber M, Chan A, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993; 136: 355-60
|
|
|
|
|
|
35) Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998; 251: 471-6
|
|
|
|
|
|
36) Beltowski J. Apelin and visfatin: unique “beneficial"adipokines upregulated in obesity？ Med Sci Monit. 2006; 12: RA112-9
|
|
|
|
|
|
37) Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001; 99: 87-92
|
|
|
|
|
|
38) Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol. 2003; 470: 171-5
|
|
|
|
|
|
39) Ishida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem. 2004; 279: 26274-9
|
|
|
|
|
|
40) Katugampola SD, Maguire JJ, Matthewson SR, et al. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol. 2001; 132: 1255-60
|
|
|
|
|
|
41) Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993; 192: 553-60
|
|
|
|
|
|
42) Kitamura K, Sakata J, Kangawa K, et al. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun. 1993; 194: 720-5
|
|
|
|
|
|
43) McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998; 393: 333-9
|
|
|
|
|
|
44) Li Y, Jiang C, Wang X, et al. Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues. Peptides. 2007; 28: 1129-43
|
|
|
|
|
|
45) Harmancey R, Senard JM, Pathak A, et al. The vasoactive peptide adrenomedullin is secreted by adipocytes and inhibits lipolysis through NO-mediated beta-adrenergic agonist oxidation. FASEB J. 2005; 19: 1045-7
|
|
|
|
|
|
46) Shimosawa T, Ogihara T, Matsui H, et al. Deficiency of adrenomedullin induces insulin resistance by increasing oxidative stress. Hypertension. 2003; 41: 1080-5
|
|
|
|
|
|
47) Allen MA, Smith PM, Ferguson AV. Adrenomedullin microinjection into the area postrema increases blood pressure. Am J Physiol. 1997; 272: R1698-703
|
|
|
|
|
|
48) Martinez A, Weaver C, Lopez J, et al. Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology. 1996; 137: 2626-32
|
|
|
|
|